1. 734PImpact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1. (23rd October 2018) Authors: Chen, L-T; Macarulla, T M; Blanc, J; Mirakhur, B; de Jong, F A; Belanger, B; Bekaii-Saab, T; Siveke, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 749PThe prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV). (23rd October 2018) Authors: Chen, L-T; Macarulla, T M; Belanger, B; Mirakhur, B; de Jong, F A; Siveke, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. O-005 Mesenchymal stem cell-derived extracellular vesicles as a coiling adjunct to improve intracranial aneurysmal healing in a rabbit model. (23rd July 2022) Authors: Belanger, B; Phelps, J; Bromley, A; Sen, A; Mitha, A Journal: Journal of neurointerventional surgery Issue: Volume 14(2022)Supplement 1 Page Start: A3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P-011 A modification of the rabbit elastase model to produce more relevant aneurysm sizes. (22nd July 2018) Authors: Belanger, B; Avery, M; Mitha, A Journal: Journal of neurointerventional surgery Issue: Volume 10(2018)Supplement 2 Page Start: A30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer. Issue 6 (5th June 2017) Authors: Adiwijaya, BS; Kim, J; Lang, I; Csõszi, T; Cubillo, A; Chen, J‐S; Wong, M; Park, JO; Kim, JS; Rau, KM; Melichar, B; Gallego, JB; Fitzgerald, J; Belanger, B; Molnar, I; Ma, WW Journal: Clinical pharmacology & therapeutics Issue: Volume 102:Issue 6(2017) Page Start: 997 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SO-005A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer. (2nd July 2019) Authors: Wainberg, Z; Boland, P; Lieu, C; Dayyani, F; Macarulla, T; Zhang, B; Belanger, B; Moore, Y; Wang, T; Maxwell, F; Dean, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗